Jaguar Health Receives Orphan Drug Designation For Crofelemer In US/EU, Non-Dilutive Funding From Mytesi Out-License, Targeting SBS-IF And MVID As Potential Blockbuster Opportunity

Jaguar has received the initial $16M payment related to the company's recently executed US out-license agreement for Mytesi® and Canalevia®-CA1, which has the potential to provide Jaguar up to an additional $22M with milestones and other potential future payments

Near-term milestones for intestinal failure program buttressed by groundbreaking results of parenteral support (PS) reduction ranging from 12 to 37% in ongoing proof-of-concept study of crofelemer in pediatric patients

Associated with significant toxicities to patients, PS has a lethal natural history, and PS reduction can potentially extend and save lives

Jaguar's rare-disease pipeline is the subject of ongoing BD discussions with potential partners, targeting NDA-ready data in 12-18 months

Jaguar presenting January 22 at Sequire Investor Summit in Puerto Rico; click here to register for event

Click here to view replay of Jaguar's January 15 fireside chat during Lytham Partners Healthcare Investor Summit

SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / January 22, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today provided updates regarding the company's strategic focus on its rare disease development program for crofelemer, which is focused on near-term milestones for the treatment of intestinal failure in patients with short bowel syndrome (SBS-IF) and microvillus inclusion disease (MVID). The company has received Orphan Drug Designation for both diseases for crofelemer in the US and EU. This development effort is being fueled by the non-dilutive funds received from the recent closing of an out-license agreement for the US rights to commercialize Mytesi and Canalevai-CA1, and is a potential blockbuster opportunity for all Jaguar stakeholders, including patients.